Clinical trial · no report yet · Phase 3
TroFuse-007
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- NCT06170788 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 2 | |
| YouTube | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan; Pembrolizumab; Supportive care measures
- Arms
- Pembrolizumab + Sacituzumab tirumotecan · Experimental
- Pembrolizumab · Active comparator
- Enrollment
- 614 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Dec 15, 2023
- Primary completion
- Jan 25, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06170788 · updated Oct 15, 2026